Notably, the EHMT2 inhibitor UNC0642 and other epigenetic drugs ranked in the final list of candidates, highlighting the relevance of epigenetic dysregulation in the context of proteasome inhibition and multiple myeloma pathogenesis (Bandini, C. et al., manuscript in preparation). The gene discussed is EHMT2; the disease is plasma cell myeloma.